Sanofi-Aventis patents on cancer drug Taxotere declared invalid

Two Sanofi-Aventis US patents for the cancer drug docetaxel, marketed as Taxotere, have been declared invalid by the Court of Appeals for the Federal Circuit.

Darren Smyth discusses the decision issued on 9 April in his latest IPKat post.